Production (Stage)
Oncolytics Biotech Inc.
ONC.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.03M | 2.78M | 2.28M | 2.46M | 2.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.88M | 6.03M | 7.26M | 5.79M | 6.47M |
| Operating Income | -4.88M | -6.03M | -7.26M | -5.79M | -6.47M |
| Income Before Tax | -4.66M | -5.71M | -6.99M | -5.23M | -5.11M |
| Income Tax Expenses | -- | 16.40K | 8.80K | 69.40K | -- |
| Earnings from Continuing Operations | -4.66M | -5.73M | -7.00M | -5.30M | -5.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.66M | -5.73M | -7.00M | -5.30M | -5.11M |
| EBIT | -4.88M | -6.03M | -7.26M | -5.79M | -6.47M |
| EBITDA | -4.86M | -6.02M | -7.23M | -5.77M | -6.45M |
| EPS Basic | -0.06 | -0.07 | -0.09 | -0.07 | -0.07 |
| Normalized Basic EPS | -0.03 | -0.05 | -0.06 | -0.04 | -0.04 |
| EPS Diluted | -0.06 | -0.07 | -0.09 | -0.07 | -0.07 |
| Normalized Diluted EPS | -0.03 | -0.05 | -0.06 | -0.04 | -0.04 |
| Average Basic Shares Outstanding | 84.63M | 77.57M | 77.02M | 76.09M | 75.24M |
| Average Diluted Shares Outstanding | 84.63M | 77.57M | 77.02M | 76.09M | 75.24M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |